ArticlePloS one2026
Respiratory and bloodstream coinfections and antimicrobial use in hospitalised patients with moderate to severe COVID-19: An Australian retrospective cohort study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCOVID-19 remains a leading infectious cause of death and hospitalisation globally. Coinfections with SARS-CoV-2 and other respiratory pathogens may result in more severe illness, however the prevalence of coinfection in Australia is unknown.
aimsThis Australian study aimed to determine the prevalence and microbiology of respiratory and bloodstream coinfections, antimicrobial use, and outcomes in hospitalised patients with moderate to severe COVID-19.
methodsThis was a retrospective cohort study of adult patients with moderate to severe COVID-19, admitted at the Sunshine Coast University Hospital from February to July 2022. Data regarding patient characteristics, comorbidities, microbiological results, hospital length of stay, intensive care unit admission, and mortality were compared between the coinfection and no-coinfection groups. Logistic regression analysis was performed to identify factors associated with coinfection.
resultsCoinfection was documented in 23 (12%) of the 190 patients admitted with moderate-severe COVID-19. Bacterial infections were the most common (54% of coinfection episodes), followed by fungal (32%), and viral (14%). Antibiotics were prescribed for 74% of patients, for a median duration of 6 days (IQR 4-8 days). Patients with coinfection had a median length of stay of 9 days (IQR: 4-19.5) compared to 6 days in the no-coinfection group (IQR: 3-9; p = 0.047). There was no mortality difference between the two groups. Patients admitted to intensive care had higher odds of coinfection compared to patients not admitted to intensive care (OR 3.39, 95% CI 1.19-9.66, p = 0.02). Severe COVID-19 and Aboriginal and Torres Strait Islander descent were also associated with coinfection. The causal nature of these relationships requires further interrogation.
conclusionsThe prevalence of respiratory and bloodstream coinfection was low in our cohort of hospitalised COVID-19 patients. Despite non-standardised microbiological testing, antibiotic use was disproportionately high. Further work is required to define risk factors and improve diagnosis of COVID-19-associated coinfection, to better inform antimicrobial stewardship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.